Keith Crandell has bought stock on 5 days since Dec 2017

Keith Crandell is a co‑founder and Managing Director of ARCH Venture Partners, a global seed and early‑stage venture capital firm focused on innovations in the life and physical sciences.( He serves as a director and 10% owner of Boundless Bio, Inc. (BOLD) through ARCH Venture Fund IX, L.P., as disclosed in his Form 3 filing with the U.S. Securities and Exchange Commission, reflecting his role as a significant corporate insider in the company.( In addition to Boundless Bio, he has played key roles in the formation and initial funding of multiple life‑science and technology companies, including 908 Devices and Twist Bioscience, and has held board positions at firms such as Quanterix, Arbor Biotechnologies, Cytrellis Biosystems, and Vizgen.(

Crandell’s career spans early work at specialty chemical and polymer company Hercules, Inc. before co‑founding ARCH Venture Partners in 1986.( He is active in industry and academic advisory roles, having served as a director of the National Venture Capital Association and on advisory boards at the University of Chicago, the Mass General Brigham Innovation Fund, and Harvard‑affiliated hospitals.( He holds an M.B.A. from the University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University, underscoring his combined technical and financial expertise in guiding high‑growth life‑science companies.(

Written by Perplexity from public sources.